Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.
- 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
- 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
- After the grant, Keresty directly owns 31,883 common shares.
No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.